KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Accounts Payables: 2011-2024

Historic Accounts Payables for Supernus Pharmaceuticals (SUPN) over the last 14 years, with Dec 2024 value amounting to $76.4 million.

  • Supernus Pharmaceuticals' Accounts Payables rose 43.28% to $108.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $108.6 million, marking a year-over-year increase of 43.28%. This contributed to the annual value of $76.4 million for FY2024, which is 4.04% down from last year.
  • According to the latest figures from FY2024, Supernus Pharmaceuticals' Accounts Payables is $76.4 million, which was down 4.04% from $79.6 million recorded in FY2023.
  • Supernus Pharmaceuticals' 5-year Accounts Payables high stood at $117.7 million for FY2021, and its period low was $76.4 million during FY2024.
  • For the 3-year period, Supernus Pharmaceuticals' Accounts Payables averaged around $84.1 million, with its median value being $79.6 million (2023).
  • Its Accounts Payables has fluctuated over the past 5 years, first surged by 58.78% in 2020, then fell by 18.13% in 2022.
  • Yearly analysis of 5 years shows Supernus Pharmaceuticals' Accounts Payables stood at $78.9 million in 2020, then surged by 49.09% to $117.7 million in 2021, then declined by 18.13% to $96.3 million in 2022, then dropped by 17.41% to $79.6 million in 2023, then fell by 4.04% to $76.4 million in 2024.